Patient Dosing

Lyra's Mid-Stage Chronic Rhinosinusitis Candidate Study Progressed, Shares Fall
Emergent Shares Decline Following Commencement Of Initial-Stage Lassa Virus Vaccine Candidate Study
Werewolf Shares Climb As Initial-Stage Solid Tumors Study Kicks-off
Emergent Shares Decline Following Commencement Of Initial-Stage Lassa Virus Vaccine Candidate Study
Werewolf Shares Climb As Initial-Stage Solid Tumors Study Kicks-off
Geron Commences Initial-Stage Rare Blood Cancer Combination Study
Kronos Bio Shares Fall After Initial-Stage Blood Cancer Study Takes-off

Patient Dosing Recent News

Aerie Shares Gain Following Patient Dosing In Late-Stage Dry Eye Disease Study
Aerie Pharmaceuticals (NASDAQ: AERI) has initiated patient dosing in the Phase 3 registrational COMET-3 study to evaluate AR-15512 ophthalmic solution as a treatment for the signs and symptoms of dry eye disease (DED).
Capricor Initiates Late-Stage Neuropsychiatric Disorder Study
Capricor Therapeutics (NASDAQ: CAPR) initiated dosing of first patient in HOPE-3, a Phase 3 clinical trial investigating CAP-1002 for treating late-stage Duchenne muscular dystrophy (DMD).
Impel Commences Mid-Stage Autism Spectrum Disorder Study
Impel Pharmaceuticals (NASDAQ: IMPL) has dosed the first patient in a Phase 2a proof-of-concept study of INP105, nasal olanzapine, a widely used atypical, second-generation antipsychotic.
Pulmatrix Commences Initial-Stage Acute Migraine Study
Pulmatrix (NASDAQ: PULM) has dosed first subject in its Phase 1 trial evaluating PUR3100 for the treatment of acute migraine. PUR3100 is an orally-inhaled Dihydroergotamine (DHE) acute migraine therapy.
Synlogic Initiates Initial-Stage Homocystinuria Study
Synlogic (NASDAQ: SYBX) has dosed its first healthy volunteer in its Phase 1 study of the investigational oral therapy SYNB1353 for the potential treatment of homocystinuria (HCU).
Immunocore Commences Initial-Stage HIV Study
Immunocore Holdings (NASDAQ: IMCR) has dosed the first patient in the first-in-human Phase 1 clinical trial of IMC-M113V for the treatment of patients with human immunodeficiency virus (HIV) infection.
Calithera Commences Mid-Stage Study Of DLBCL Candidate
Calithera Biosciences, Inc. (NASDAQ: CALA) initiates dosing first patient in the phase 2 clinical trial evaluating its spleen tyrosine kinase (SYK) inhibitor mivavotinib (CB-659) in patients with relapsed/refractory non-germinal center B-cell like (non-GCB) diffuse large B-cell lymphoma (DLBCL).
Biomea Fusion Commences Initial-Stage Study For Plasma Cell Cancer Setting
Biomea Fusion (NASDAQ: BMEA) has dosed the the first patient in the multiple myeloma (MM) cohort of the Phase I clinical trial evaluating BMF-219, a covalent menin inhibitor. Multiple myeloma (MM) is a cancer of plasma cells, which make antibodies (immunoglobulins) and are mainly located in the bone marrow.